Cardax

CDXI

Biotechnology · Healthcare

Price

$0.00

+0.00 (+0.00%)

Market Cap

$80

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+95.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 381K (2016) → 745K (2020)

Cardax, Inc. is a small biotechnology company focused on developing drugs that reduce inflammation in the body. Its lead compound is ZYN002, a synthetic version of astaxanthin, a natural antioxidant found in seafood. The company targets conditions like gout and other inflammatory diseases, and its main customers would be patients and healthcare providers if its drugs reach the market.

Cardax earns very little revenue today because its drugs are still in clinical development and have not been approved for sale. It operates primarily in the United States and is a micro-cap company with a market value close to zero, meaning it is very small and carries significant financial risk. The company's biggest challenge is funding ongoing research and successfully completing clinical trials, since failing a trial or running out of cash could threaten its survival.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-26.8% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-10.6% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$136,780/ year

↓ Declining (-57% vs prior year)

25.4% of revenue

In line with sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

26.5%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~1 months

$58,650 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

Cardax has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

63.3%

Premium pricing power — 63.3% gross margin

Operating Margin

-737.6%

Losing money on operations — -737.6%

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-27.3%

Shrinking sales (-27.3% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-313.1%

Burning cash (-313.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial